Europe Backs a Weekly Shot. The Commission Has Not Signed.

The European Medicines Agency's human medicines committee met from 12 to 15 October and, on 16 October, published the list. Six new medicines recommended. One of them is Yuviwel, the brand name for navepegritide, a once-weekly injection for children with achondroplasia whose growth plates are still open, from the age of two.

Ascendis Pharma, in Copenhagen, said the European Commission decision should land in the fourth quarter of 2026. If it does, the company expects a German launch under the Yuviwel name in the first quarter of 2027. A committee opinion is a recommendation. The Commission is the signature.

The opinion rests on three randomised, placebo-controlled trials and up to three years of extension data. In the pivotal ApproaCH trial, 84 children aged 2 to 11 were randomised two-to-one. The dose was 100 micrograms per kilogram, once a week, under the skin. At week 52, annualised growth velocity was 5.89 centimetres a year on the drug and 4.41 on placebo. The least-squares difference was 1.49 centimetres a year, confidence interval 1.05 to 1.93. Among the 53 children aged five and older, the difference was 1.78 centimetres a year. The drug is a C-type natriuretic peptide prodrug, built to give a steady signal against the overactive FGFR3 receptor that causes the short stature. It does not switch that receptor off.

The US Food and Drug Administration approved the same molecule on 27 February 2026, under accelerated approval. That pathway still wants a confirmatory showing that the centimetres become a clinical benefit.

Key Facts

• CHMP positive opinion published 16 October 2026
• Navepegritide, brand Yuviwel, once a week, children aged 2 and older with open growth plates
• ApproaCH trial: 84 children, 5.89 versus 4.41 centimetres a year at week 52
• Difference: 1.49 centimetres a year, 95 percent confidence interval 1.05 to 1.93
• US approval: 27 February 2026, accelerated
• European Commission decision expected in the fourth quarter of 2026

Why This Matters

A centimetre and a half a year is a measured change in a condition with few drugs, and it is small enough to say out loud without dressing it up. The missing Commission signature is the sentence that keeps it honest.

What We Don't Know Yet

Whether the Commission agrees, and on what label. Whether accelerated approval in the United States converts. What share of children avoid surgery. The open-label years are not a new randomised result.

Sources: European Medicines Agency · Ascendis Pharma